Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Mereo BioPharma Group plcNASDAQ: MREO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow shrinks to $0
Q1 FY2026 financing cash flow was $0, compared with $422K a year earlier. Trailing-twelve-month financing cash flow was -$95.27K. Over 3 fiscal years it compounded at +17.8% a year.
Context
- Financing cash flow amounted to 65.4% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$23.82K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 327K USD
- Year-over-year change
- -99.3%
- 4-year CAGR
- -76.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 327K | -99.3% |
| FY2024 | 2024-12-31 | 46.15M | +478.8% |
| FY2023 | 2023-12-31 | 7.97M | +3886.5% |
| FY2022 | 2022-12-31 | 200K | -99.8% |
| FY2021 | 2021-12-31 | 104.8M | — |
Financing Cash Flow vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.2% is the 8th highest of 10, against a peer median of +3.6%.
- Financing cash flow amounts to 19.1% of revenue for MREO, versus a peer median of 11.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $250.31M USD | +66.3% | +271.0% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $219.24M USD | +164739.1% | +946.8% | — |
| LTM Mar 2026 | $151.78M USD | +62.0% | +41.1% | — | |
| LTM Mar 2026 | $141.48M USD | +10580.1% | +128.2% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $112.79M USD | +3.6% | — | — |
| LTM Mar 2026 | €1.63M EUR | -102.3% | -61.5% | 12.2% | |
| LTM Dec 2025 | CHF 1.02M CHF | -9.0% | -10.2% | 28.5% | |
| FY2025 | A$525.12K AUD | -100.6% | — | 10.4% | |
| LTM Mar 2026 | $191.89K USD | -76.4% | -2.7% | — | |
| LTM Mar 2026 | $95.27K USD | -100.2% | +17.8% | 19.1% | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
| Peer median (excluding MREO) | — | +3.6% | +19.2% | 11.3% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 19.22M | (42.22M) | (29.47M) | (43.25M) | (41.88M) |
| Depreciation & Amortization | 866.47K | 889K | 1.06M | 1.09M | 622K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.46M | 4.77M | 4.92M | 7.39M | 7.6M |
| Change in Working Capital | (2.49M) | (2.35M) | (1.59M) | (369K) | (3.21M) |
| Accounts Receivables | (794.94K) | (3.47M) | 456K | (1.65M) | 1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 617K | (1.26M) | 146K | (1.38M) |
| Other Working Capital | (1.7M) | 498K | (786K) | 1.13M | (3.23M) |
| Other Non-Cash Items | (29.12M) | (9.91M) | 3.94M | 2.31M | 5.9M |
| Operating Cash Flow | (7.07M) | (48.82M) | (21.13M) | (32.83M) | (30.97M) |
| Capital Expenditures | (722.06K) | (13K) | (419K) | (699K) | (20K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 153.86K | 2M | (419K) | 0 | 0 |
| Investing Cash Flow | (568.2K) | 1.99M | (419K) | (699K) | (20K) |
| Debt Repayment | (933.95K) | 0 | (3.19M) | 0 | 0 |
| Common Stock Issued | 105.99M | 0 | 11.61M | 47M | 327.76K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (253.73K) | 200K | 24K | (853K) | (764) |
| Financing Cash Flow | 104.8M | 200K | 7.97M | 46.15M | 327K |
| Effect of Forex Changes | (1.57M) | (12.58M) | 2.82M | (233K) | 1.93M |
| Net Change in Cash | 95.59M | (59.22M) | (10.76M) | 12.38M | (28.81M) |
| Free Cash Flow | (7.79M) | (48.83M) | (21.55M) | (33.53M) | (30.99M) |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.